Latest news

Director/PDMR Shareholding

29 December 2022

Results of AGM

16 December 2022

AGM Statement

16 December 2022

Notice of AGM, Annual Report and Accounts

24 November 2022

Find out more


TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies

Find out more large-arrow.png


Sareum's innovative pipeline is focused on the TYK/JAK cell signalling family.

Find out more large-arrow.png

External Presentationssmall-arrow.png

IMC AGM, Dec 2022
IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022

IMC Half Year Results, Feb 2022